ClinicalTrials.gg
CompletedNCT01340586Updated Oct 11, 2016Results posted

Pharmacokinetics and Pharmacodynamics of Apixaban in Subjects on Hemodialysis

A Phase 1 interventional study of Apixaban and Apixaban in End Stage Renal Disease, sponsored by Bristol-Myers Squibb. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-10-11.

Sponsored by Bristol-Myers Squibb · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 765 studies in Kidney Failure, Chronic with a site in United States — 65 open to participants now, 97 under way, 9 of them phase 3. Kidney Failure, Chronic · United States.

Enrollment
477th of 638
18 · median 48
Started
2011
with 31 others
Phase 1
89 of 765
8 open now
Registered
249th of 765
by date

Among the 765 studies in Kidney Failure, Chronic with a site in United States, this one is the 477th largest by enrollment of the 638 interventional ones that give a count, is one of 32 that started in 2011, is one of 89 in phase 1, and was the 249th registered.

Kidney Failure, Chronic

2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

65 of the 765 studies in Kidney Failure, Chronic with a site in United States are open now. Recruiting first, the newest first:

60 more — sign in →

All 65 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 765 studies in Kidney Failure, Chronic with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to assess the pharmacokinetics of a single oral dose of 5 mg Apixaban in subjects with normal renal function and subjects with end stage renal disease (ESRD) maintained with hemodialysis.

Read the detailed description

Primary Purpose : To provide a clear understanding of the pharmacokinetics of Apixaban in subjects with ESRD and to determine the effect of hemodialysis on Apixaban pharmacokinetics .

03

Conditions studied

  • End Stage Renal Disease

Keywords

  • PHARMACOKINETIC
  • NOS
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The signed form.
  • Subjects with normal renal function classified based on calculated (CLCr) determined by the cockcroft-gault calculation.
  • Eligible subjects with ESRD that is maintained with chronic and stable hemodialysis.

Exclusion criteria

Exclusion Criteria:

  • Any history of abnormal bleeding or coagulation disorders including those in a first degree relative under 50 years of age.
  • History of significant head injury within the last two years.
  • Any gastrointestinal surgery that could impact the absorption of study drug.
  • Not expected to continue the hemodialysis treatment for the duration of the study.
  • , PT, or aPTT above the , unless agreed upon between the investigator and BMS medical monitor.
  • History of allergy to Apixaban or Factor Xa inhibitors.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Group A: Apixaban

    Drug: Apixaban

  • Experimental
    Group B: Apixaban

    Drug: Apixaban

Interventions

  • Tablets, Oral, 5 mg, Once, 4 days

  • Tablets, Oral, 5 mg, Twice, 15 days

06

What researchers measure

Primary outcomes

  1. Geometric Mean of Maximum Observed Plasma Concentration (Cmax) of Single 5mg Oral Dose of Apixaban

    Maximum observed plasma concentration (Cmax) was measured by plasma concentration of apixaban over time. The geometric means are reported in nanograms per milliliter (ng/mL).

    Time frame: 24 hours pre-dose to 72 hours post-dose

  2. Geometric Mean of Maximum Observed Plasma Concentration (Cmax) of Metabolite BMS-730823

    Maximum observed plasma concentration (Cmax) was measured by plasma concentration of BMS-730823 over time. The geometric means are reported in nanograms per milliliter (ng/mL).

    Time frame: From 24 hours pre-dose to 72 hours post-dose

  3. Geometric Mean of Area Under the Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration (AUC(0-T)) of Single 5mg Oral Dose of Apixaban

    Area under the concentration-time curve from time zero to time of the last quantifiable concentration (AUC(0-T)) was measured by plasma concentration of apixaban over time. The geometric means are reported in nanogram hours per milliliter (ng\*h/mL).

    Time frame: 24 hours pre-dose to 72 hours post-dose

  4. Geometric Mean of Area Under the Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration (AUC(0-T)) of Metabolite BMS-730823

    Area under the concentration-time curve from time zero to time of the last quantifiable concentration (AUC(0-T)) was measured by plasma concentration of BMS-730823 over time. The geometric means are reported in nanogram hours per milliliter (ng\*h/mL).

    Time frame: From 24 hours pre-dose to 72 hours post-dose

  5. Geometric Mean of Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) of Single 5mg Oral Dose of Apixaban

    The area under the concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) was measured by plasma concentration of apixaban over time. The geometric means are reported in nanogram hours per milliliter (ng\*h/mL).

    Time frame: From 24 hours pre-dose to 72 hours post-dose

  6. Geometric Mean of Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) of BMS-730823

    The area under the concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) was measured by plasma concentration of BMS-730823 over time. The geometric means are reported in nanogram hours per milliliter (ng\*h/mL).

    Time frame: 24 hours pre-dose to 72 hours post-dose

  7. Mean Plasma Terminal Half-life (T-Half) of Single 5mg Oral Dose of Apixaban

    Plasma terminal half-life (T-Half) for apixaban was derived from plasma concentrations versus time data. Means were reported in hours.

    Time frame: From 24 hours pre-dose to 72 hours post-dose

  8. Mean Plasma Terminal Half-life (T-Half) of BMS-730823

    Mean plasma terminal half-life (T-Half) for BMS-730823 was derived from plasma concentrations versus time data.

    Time frame: 24 hours pre-dose to 72 hours post-dose

  9. Median Time of Maximum Observed Plasma Concentration (Tmax) of a Single 5 mg Oral Dose of Apixaban

    Time of maximum observed plasma concentration (Tmax) for apixaban was derived from plasma concentrations versus time data. Medians were reported in hours.

    Time frame: From 24 hours pre-dose to 72 hours post-dose

  10. Median Time of Maximum Observed Plasma Concentration (Tmax) of Metabolite BMS-730823

    Time of maximum observed plasma concentration (Tmax) for BMS-730823 was derived from plasma concentrations versus time data. Medians were reported in hours.

    Time frame: From 24 hours pre-dose to 72 hours post-dose

  11. Geometric Mean of Area Under the Plasma Concentration-Time Curve From 2 to 6 Hours (AUC(2-6)) for Apixaban

    Area under the plasma concentration-time curve from 2 hours to 6 hours (AUC(2-6) for Apixaban was measured in participants with ESRD during dialysis in Period 1 only. Geometric Means were reported in nanogram hours per milliliter (ng\*hr/mL) and were determined from blood samples both entering and exiting the dialyzer.

    Time frame: 2 to 6 hours post-dose

  12. Geometric Mean of Area Under the Plasma Concentration-Time Curve From 2 to 6 Hours (AUC(2-6)) for BMS-730823

    Area under the plasma concentration-time curve from 2 hours to 6 hours (AUC(2-6) for BMS-730823 was measured in participants with ESRD during dialysis in Period 1 only. Geometric Means were reported in nanogram hours per milliliter (ng\*hr/mL) and were determined from blood samples both entering and exiting the dialyzer.

    Time frame: 2 to 6 hours post-dose

  13. Mean Percent Dose of Apixaban Recovered in Urine (%UR)

    The percent dose recovered in urine was calculated by dividing the cumulative amount of unchanged apixaban excreted in urine from the time of dose up to 72 hours post-dose by the apixaban dose administered.

    Time frame: 24 hours pre-dose to 72 hours post-dose

  14. Mean Percent Dose of Apixaban Recovered in Dialysate (%DR)

    Percent dose of Apixaban recovered in dialysate (%DR) was calculated by dividing the cumulative amount of apixaban excreted in each dialysate collection over 2-6 hours (DR(2-6)) by the apixaban dose. %DR was recorded only in period 1.

    Time frame: 2 to 6 hours post-dose

  15. Mean Renal Clearance (CLR) of Apixaban

    Renal clearance (CLR) was calculated by dividing the cumulative amount of apixaban excreted in urine by the respective cumulative plasma AUC over the same urine collection interval. Geometric means were reported in milliliters per minute (mL/min).

    Time frame: 24 hours pre-dose to 72 hours post-dose

  16. Mean Renal Clearance (CLR) of BMS-730823

    Renal clearance (CLR) was calculated by dividing the cumulative amount of BMS-730823 excreted in urine by the respective cumulative plasma AUC over the same urine collection interval. Geometric means were reported in milliliters per minute (mL/min).

    Time frame: 24 hours pre-dose to 72 hours post-dose

  17. Mean Hemodialysis Clearance (CLD) of Apixaban

    Hemodialysis clearance (CLD) was calculated by dividing the cumulative amount of apixaban excreted in dialysate by the respective cumulative plasma AUC over the same dialysate collection interval (AUC(2-6) entering). CLD measurements occurred only in period 1. Geometric means were reported in milliliters per minute (mL/min).

    Time frame: 2 to 6 hours post-dose

  18. Mean Hemodialysis Clearance (CLD) of BMS-730823

    Hemodialysis clearance (CLD) was calculated by dividing the cumulative amount of BMS-730823 excreted in dialysate by the respective cumulative plasma AUC over the same dialysate collection interval (AUC(2-6) entering). CLD measurements occurred only in period 1. Geometric means were reported in milliliters per minute (mL/min).

    Time frame: 2 to 6 hours post-dose

  19. Percentage of Apixaban Extracted During Hemodialysis

    The percentage of apixaban extracted during hemodialysis (extraction ratio) was calculated using the formula \[plasma AUC(2-6) exiting - AUC(2-6) entering\] / \[AUC(2-6) entering\] and converted to a percentage. The extraction ratio was measured in period 1 only, and was reported as a percentage.

    Time frame: 2 to 6 hours post-dose

  20. Percentage of BMS-730823 Extracted During Hemodialysis

    The percentage of BMS-730823 extracted during hemodialysis (extraction ratio) was calculated using the formula \[plasma AUC(2-6)exiting - AUC(2-6)entering\] / \[AUC(2-6) entering\] and converted to a percentage. The extraction ratio was measured in period 1 only, and was reported as a percentage.

    Time frame: 2 to 6 hours post-dose

Secondary outcomes

  1. Mean Maximum Percent Change From Baseline International Normalized Ratio (INR) Following a Single 5 mg Oral Dose of Apixaban

    The mean maximum percent change in baseline for INR was reported for each arm. Baseline measurements were assessed up to 24 hours prior to Day 1 dosing.

    Time frame: From 24 hours pre-dose to 72 hours post-dose

  2. Mean Maximum Percent Change From Baseline Prothrombin Time (PT) Following a Single 5 mg Oral Dose of Apixaban

    The mean maximum percent change in Prothrombin Time (PT) from baseline was reported for all treated participants. Baseline measurements were assessed up to 24 hours prior to Day 1 dosing.

    Time frame: From 24 hours pre-dose to 72 hours post-dose

  3. Mean Maximum Percent Change From Baseline Activated Partial Thromboplastin Time (aPTT) Following a Single Oral Dose of 5 mg Apixaban

    The mean maximum percent change in Activated Partial Thromboplastin Time (aPTT) from baseline was reported for all treated participants. Baseline measurements were assessed up to 24 hours prior to Day 1 dosing.

    Time frame: From 24 hours pre-dose to 72 hours post-dose

  4. Mean Peak Anti-FXa Activity Following a Single Oral Dose of 5 mg Apixaban

    Anti-FXa activity was assessed from an activity-time profile for doses both before and after hemodialysis. Maximal means were reported in International Units per milliliter (IU/mL).

    Time frame: From 24 hours pre-dose to 72 hours post-dose

Other outcomes

  1. Number of Participants With Laboratory Marked Abnormalities

    ULN=Upper Limit of Normal, LLN=Lower Limit of Normal, Pre-Rx= Baseline value. BUN=Blood Urea Nitrogen (mmol/L=millimoles per Liter): High if BUN \> 1.1\*ULN (if Pre-Rx\>ULN: \>1.25\*Pre-Rx). Platelet count (\*10\^9 cell/L): Low if Platelet Count \< 0.85\*LLN (if Pre-Rx\<LLN: \<0.85\*Pre-Rx). Creatine (umol/L=micromoles per Liter): High if Creatine \> 1.5\*ULN (if Pre-Rx\>ULN: \>1.33\*Pre-Rx). Calcium, Total (mmol/L): High if Calcium \> 1.5\*ULN (if Pre-Rx\>ULN: \>1.33\*Pre-Rx). Potassium, serum (mmol/L): High if Potassium \> 1.1\*ULN (if Pre-Rx\>ULN: \>1.1\*Pre-Rx; if Pre-Rx\<LLN: \>ULN). Phosphorus, Inorganic (mmol/L): Low if Phosphate \< 0.85\*LLN (if Pre-Rx\>ULN: \<LLN). Lactate dehydrogenase (U/L=Units per Liter): High if Lactate Dehydrogenase \> 1.25\*ULN (if Pre-Rx\>ULN: \>1.5\*Pre-Rx).

    Time frame: From 24 hours pre-dose to 72 hours post-dose

  2. Number of Participants Who Died or Experienced Serious Adverse Events (SAEs) or Adverse Events Leading to Discontinuation

    The number of participants who died or experienced SAEs or AEs leading to discontinuation was reported for each arm. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug. Grade (Gr) 1=Mild, Gr 2=Moderate, Gr 3=Severe, Gr 4= Potentially Life-threatening or disabling.

    Time frame: From Day 1 to 30 days post study discontinuation

07

Results

Posted Oct 11, 2016

Participant flow

Participant flow — Overall Study
MilestoneNormal Renal FunctionESRD Maintained With Hemodialysis
Started88
Completed88
Not completed00

Outcome measures

PrimaryGeometric Mean of Maximum Observed Plasma Concentration (Cmax) of Single 5mg Oral Dose of Apixaban

Maximum observed plasma concentration (Cmax) was measured by plasma concentration of apixaban over time. The geometric means are reported in nanograms per milliliter (ng/mL).

Time frame:
24 hours pre-dose to 72 hours post-dose
Reported as:
Geometric mean · ng/mL
Geometric Mean of Maximum Observed Plasma Concentration (Cmax) of Single 5mg Oral Dose of Apixaban
ng/mLNormal Renal FunctionESRD Dose Before HemodialysisESRD Dose After Hemodialysis
Geometric Mean of Maximum Observed Plasma Concentration (Cmax) of Single 5mg Oral Dose of Apixaban125.6 ± 2998.9 ± 29113.6 ± 31
Statistical analysis
  • Normal Renal Function vs ESRD Dose Before Hemodialysis · Geometric mean ratio: 0.787 · 90% CI 0.616 to 1.006
  • Normal Renal Function vs ESRD Dose After Hemodialysis · Geometric mean ratio: 0.904 · 90% CI 0.697 to 1.173
  • ESRD Dose Before Hemodialysis vs ESRD Dose After Hemodialysis · Geometric mean ratio: 0.871 · 90% CI 0.723 to 1.049
PrimaryGeometric Mean of Maximum Observed Plasma Concentration (Cmax) of Metabolite BMS-730823

Maximum observed plasma concentration (Cmax) was measured by plasma concentration of BMS-730823 over time. The geometric means are reported in nanograms per milliliter (ng/mL).

Time frame:
From 24 hours pre-dose to 72 hours post-dose
Reported as:
Geometric mean · ng/mL
Geometric Mean of Maximum Observed Plasma Concentration (Cmax) of Metabolite BMS-730823
ng/mLNormal Renal FunctionESRD Dose Before HemodialysisESRD Dose After Hemodialysis
Geometric Mean of Maximum Observed Plasma Concentration (Cmax) of Metabolite BMS-73082310.8 ± 3815.9 ± 4820.0 ± 39
PrimaryGeometric Mean of Area Under the Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration (AUC(0-T)) of Single 5mg Oral Dose of Apixaban

Area under the concentration-time curve from time zero to time of the last quantifiable concentration (AUC(0-T)) was measured by plasma concentration of apixaban over time. The geometric means are reported in nanogram hours per milliliter (ng\*h/mL).

Time frame:
24 hours pre-dose to 72 hours post-dose
Reported as:
Geometric mean · ng*hr/mL
Geometric Mean of Area Under the Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration (AUC(0-T)) of Single 5mg Oral Dose of Apixaban
ng*hr/mLNormal Renal FunctionESRD Dose Before HemodialysisESRD Dose After Hemodialysis
Geometric Mean of Area Under the Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration (AUC(0-T)) of Single 5mg Oral Dose of Apixaban1205 ± 291430 ± 411673 ± 24
Statistical analysis
  • Normal Renal Function vs ESRD Dose Before Hemodialysis · Geometric mean ratio: 1.187 · 90% CI 0.907 to 1.553
  • Normal Renal Function vs ESRD Dose After Hemodialysis · Geometric mean ratio: 1.389 · 90% CI 1.097 to 1.758
  • ESRD Dose Before Hemodialysis vs ESRD Dose After Hemodialysis · Geometric mean ratio: 0.855 · 90% CI 0.707 to 1.033
PrimaryGeometric Mean of Area Under the Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration (AUC(0-T)) of Metabolite BMS-730823

Area under the concentration-time curve from time zero to time of the last quantifiable concentration (AUC(0-T)) was measured by plasma concentration of BMS-730823 over time. The geometric means are reported in nanogram hours per milliliter (ng\*h/mL).

Time frame:
From 24 hours pre-dose to 72 hours post-dose
Reported as:
Geometric mean · ng*hr/mL
Geometric Mean of Area Under the Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration (AUC(0-T)) of Metabolite BMS-730823
ng*hr/mLNormal Renal FunctionESRD Dose Before HemodialysisESRD Dose After Hemodialysis
Geometric Mean of Area Under the Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration (AUC(0-T)) of Metabolite BMS-730823205 ± 69746 ± 56953 ± 33
PrimaryGeometric Mean of Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) of Single 5mg Oral Dose of Apixaban

The area under the concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) was measured by plasma concentration of apixaban over time. The geometric means are reported in nanogram hours per milliliter (ng\*h/mL).

Time frame:
From 24 hours pre-dose to 72 hours post-dose
Reported as:
Geometric mean · ng*hr/mL
Geometric Mean of Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) of Single 5mg Oral Dose of Apixaban
ng*hr/mLNormal Renal FunctionESRD Dose Before HemodialysisESRD Dose After Hemodialysis
Geometric Mean of Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) of Single 5mg Oral Dose of Apixaban1265 ± 301474 ± 441717 ± 24
Statistical analysis
  • Normal Renal Function vs ESRD Dose Before Hemodialysis · Geometric mean ratio: 1.165 · 90% CI 0.880 to 1.543
  • Normal Renal Function vs ESRD Dose After Hemodialysis · Geometric mean ratio: 1.357 · 90% CI 1.066 to 1.728
  • ESRD Dose Before Hemodialysis vs ESRD Dose After Hemodialysis · Geometric mean ratio: 0.858 · 90% CI 0.707 to 1.042
PrimaryGeometric Mean of Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) of BMS-730823

The area under the concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) was measured by plasma concentration of BMS-730823 over time. The geometric means are reported in nanogram hours per milliliter (ng\*h/mL).

Time frame:
24 hours pre-dose to 72 hours post-dose
Reported as:
Mean · ng*h/mL
Geometric Mean of Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) of BMS-730823
ng*h/mLNormal Renal FunctionESRD Dose Before HemodialysisESRD Dose After Hemodialysis
Geometric Mean of Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinite Time (AUC(INF)) of BMS-730823NA ± NANA ± NANA ± NA
PrimaryMean Plasma Terminal Half-life (T-Half) of Single 5mg Oral Dose of Apixaban

Plasma terminal half-life (T-Half) for apixaban was derived from plasma concentrations versus time data. Means were reported in hours.

Time frame:
From 24 hours pre-dose to 72 hours post-dose
Reported as:
Mean · hours
Mean Plasma Terminal Half-life (T-Half) of Single 5mg Oral Dose of Apixaban
hoursNormal Renal FunctionESRD Dose Before HemodialysisESRD Dose After Hemodialysis
Mean Plasma Terminal Half-life (T-Half) of Single 5mg Oral Dose of Apixaban20.0 ± 14.4512.5 ± 3.1412.7 ± 3.40
PrimaryMean Plasma Terminal Half-life (T-Half) of BMS-730823

Mean plasma terminal half-life (T-Half) for BMS-730823 was derived from plasma concentrations versus time data.

Time frame:
24 hours pre-dose to 72 hours post-dose
Reported as:
Mean · hours
Mean Plasma Terminal Half-life (T-Half) of BMS-730823
hoursESRD Maintained With Hemodialysis
Mean Plasma Terminal Half-life (T-Half) of BMS-730823NA ± NA
PrimaryMedian Time of Maximum Observed Plasma Concentration (Tmax) of a Single 5 mg Oral Dose of Apixaban

Time of maximum observed plasma concentration (Tmax) for apixaban was derived from plasma concentrations versus time data. Medians were reported in hours.

Time frame:
From 24 hours pre-dose to 72 hours post-dose
Reported as:
Median · hours
Median Time of Maximum Observed Plasma Concentration (Tmax) of a Single 5 mg Oral Dose of Apixaban
hoursNormal Renal FunctionESRD Dose Before HemodialysisESRD Dose After Hemodialysis
Median Time of Maximum Observed Plasma Concentration (Tmax) of a Single 5 mg Oral Dose of Apixaban2.00 (1.0 to 4.0)2.00 (1.0 to 6.0)2.00 (2.0 to 6.0)
PrimaryMedian Time of Maximum Observed Plasma Concentration (Tmax) of Metabolite BMS-730823

Time of maximum observed plasma concentration (Tmax) for BMS-730823 was derived from plasma concentrations versus time data. Medians were reported in hours.

Time frame:
From 24 hours pre-dose to 72 hours post-dose
Reported as:
Median · hours
Median Time of Maximum Observed Plasma Concentration (Tmax) of Metabolite BMS-730823
hoursNormal Renal FunctionESRD Dose Before HemodialysisESRD Dose After Hemodialysis
Median Time of Maximum Observed Plasma Concentration (Tmax) of Metabolite BMS-7308239.00 (6.0 to 12.0)15.00 (8.0 to 60.0)21.00 (12.0 to 36.0)
PrimaryGeometric Mean of Area Under the Plasma Concentration-Time Curve From 2 to 6 Hours (AUC(2-6)) for Apixaban

Area under the plasma concentration-time curve from 2 hours to 6 hours (AUC(2-6) for Apixaban was measured in participants with ESRD during dialysis in Period 1 only. Geometric Means were reported in nanogram hours per milliliter (ng\*hr/mL) and were determined from blood samples both entering and exiting the dialyzer.

Time frame:
2 to 6 hours post-dose
Reported as:
Geometric mean · ng*hr/mL
Geometric Mean of Area Under the Plasma Concentration-Time Curve From 2 to 6 Hours (AUC(2-6)) for Apixaban
ng*hr/mLESRD Maintained With Hemodialysis
Blood entering dialyzer309 ± 29
Blood exiting dialyzer312 ± 28
PrimaryGeometric Mean of Area Under the Plasma Concentration-Time Curve From 2 to 6 Hours (AUC(2-6)) for BMS-730823

Area under the plasma concentration-time curve from 2 hours to 6 hours (AUC(2-6) for BMS-730823 was measured in participants with ESRD during dialysis in Period 1 only. Geometric Means were reported in nanogram hours per milliliter (ng\*hr/mL) and were determined from blood samples both entering and exiting the dialyzer.

Time frame:
2 to 6 hours post-dose
Reported as:
Geometric mean · ng*hr/mL
Geometric Mean of Area Under the Plasma Concentration-Time Curve From 2 to 6 Hours (AUC(2-6)) for BMS-730823
ng*hr/mLESRD Maintained With Hemodialysis
Blood entering dialyzer15.0 ± 102
Blood exiting dialyzer17.7 ± 96
PrimaryMean Percent Dose of Apixaban Recovered in Urine (%UR)

The percent dose recovered in urine was calculated by dividing the cumulative amount of unchanged apixaban excreted in urine from the time of dose up to 72 hours post-dose by the apixaban dose administered.

Time frame:
24 hours pre-dose to 72 hours post-dose
Reported as:
Mean · percent of dose recovered in urine
Mean Percent Dose of Apixaban Recovered in Urine (%UR)
percent of dose recovered in urineNormal Renal FunctionESRD Dose Before HemodialysisESRD Dose After Hemodialysis
Mean Percent Dose of Apixaban Recovered in Urine (%UR)18.397 ± 8.55450.145 ± 0.08810.181 ± 0.1391
PrimaryMean Percent Dose of Apixaban Recovered in Dialysate (%DR)

Percent dose of Apixaban recovered in dialysate (%DR) was calculated by dividing the cumulative amount of apixaban excreted in each dialysate collection over 2-6 hours (DR(2-6)) by the apixaban dose. %DR was recorded only in period 1.

Time frame:
2 to 6 hours post-dose
Reported as:
Mean · percent of dose recovered in dialysate
Mean Percent Dose of Apixaban Recovered in Dialysate (%DR)
percent of dose recovered in dialysateESRD Maintained With Hemodialysis
Mean Percent Dose of Apixaban Recovered in Dialysate (%DR)6.68 ± 1.408
PrimaryMean Renal Clearance (CLR) of Apixaban

Renal clearance (CLR) was calculated by dividing the cumulative amount of apixaban excreted in urine by the respective cumulative plasma AUC over the same urine collection interval. Geometric means were reported in milliliters per minute (mL/min).

Time frame:
24 hours pre-dose to 72 hours post-dose
Reported as:
Geometric mean · mL/min
Mean Renal Clearance (CLR) of Apixaban
mL/minNormal Renal FunctionESRD Dose Before HemodialysisESRD Dose After Hemodialysis
Mean Renal Clearance (CLR) of Apixaban11.263 ± 440.020 ± 700.020 ± 80
PrimaryMean Renal Clearance (CLR) of BMS-730823

Renal clearance (CLR) was calculated by dividing the cumulative amount of BMS-730823 excreted in urine by the respective cumulative plasma AUC over the same urine collection interval. Geometric means were reported in milliliters per minute (mL/min).

Time frame:
24 hours pre-dose to 72 hours post-dose
Reported as:
Geometric mean · mL/min
Mean Renal Clearance (CLR) of BMS-730823
mL/minNormal Renal FunctionESRD Dose Before HemodialysisESRD Dose After Hemodialysis
Mean Renal Clearance (CLR) of BMS-7308236.36 ± 62NA ± NANA ± NA
PrimaryMean Hemodialysis Clearance (CLD) of Apixaban

Hemodialysis clearance (CLD) was calculated by dividing the cumulative amount of apixaban excreted in dialysate by the respective cumulative plasma AUC over the same dialysate collection interval (AUC(2-6) entering). CLD measurements occurred only in period 1. Geometric means were reported in milliliters per minute (mL/min).

Time frame:
2 to 6 hours post-dose
Reported as:
Geometric mean · mL/min
Mean Hemodialysis Clearance (CLD) of Apixaban
mL/minESRD Maintained With Hemodialysis
Mean Hemodialysis Clearance (CLD) of Apixaban17.7 ± 19
PrimaryMean Hemodialysis Clearance (CLD) of BMS-730823

Hemodialysis clearance (CLD) was calculated by dividing the cumulative amount of BMS-730823 excreted in dialysate by the respective cumulative plasma AUC over the same dialysate collection interval (AUC(2-6) entering). CLD measurements occurred only in period 1. Geometric means were reported in milliliters per minute (mL/min).

Time frame:
2 to 6 hours post-dose
Reported as:
Mean · mL/min
Mean Hemodialysis Clearance (CLD) of BMS-730823
mL/minESRD Maintained With Hemodialysis
Mean Hemodialysis Clearance (CLD) of BMS-730823NA ± NA
PrimaryPercentage of Apixaban Extracted During Hemodialysis

The percentage of apixaban extracted during hemodialysis (extraction ratio) was calculated using the formula \[plasma AUC(2-6) exiting - AUC(2-6) entering\] / \[AUC(2-6) entering\] and converted to a percentage. The extraction ratio was measured in period 1 only, and was reported as a percentage.

Time frame:
2 to 6 hours post-dose
Reported as:
Mean · percentage of apixaban extracted
Percentage of Apixaban Extracted During Hemodialysis
percentage of apixaban extractedESRD Maintained With Hemodialysis
Percentage of Apixaban Extracted During Hemodialysis-1.1 ± 5.65
PrimaryPercentage of BMS-730823 Extracted During Hemodialysis

The percentage of BMS-730823 extracted during hemodialysis (extraction ratio) was calculated using the formula \[plasma AUC(2-6)exiting - AUC(2-6)entering\] / \[AUC(2-6) entering\] and converted to a percentage. The extraction ratio was measured in period 1 only, and was reported as a percentage.

Time frame:
2 to 6 hours post-dose
Reported as:
Mean · percentage of BMS-730823 extracted
Percentage of BMS-730823 Extracted During Hemodialysis
percentage of BMS-730823 extractedESRD Maintained With Hemodialysis
Percentage of BMS-730823 Extracted During Hemodialysis-19.9 ± 25.32
SecondaryMean Maximum Percent Change From Baseline International Normalized Ratio (INR) Following a Single 5 mg Oral Dose of Apixaban

The mean maximum percent change in baseline for INR was reported for each arm. Baseline measurements were assessed up to 24 hours prior to Day 1 dosing.

Time frame:
From 24 hours pre-dose to 72 hours post-dose
Reported as:
Mean · maximum percent change from baseline
Mean Maximum Percent Change From Baseline International Normalized Ratio (INR) Following a Single 5 mg Oral Dose of Apixaban
maximum percent change from baselineNormal Renal FunctionESRD Dose Before HemodialysisESRD Dose After Hemodialysis
Mean Maximum Percent Change From Baseline International Normalized Ratio (INR) Following a Single 5 mg Oral Dose of Apixaban31.5 ± 56.5916.6 ± 10.6016.8 ± 7.15
SecondaryMean Maximum Percent Change From Baseline Prothrombin Time (PT) Following a Single 5 mg Oral Dose of Apixaban

The mean maximum percent change in Prothrombin Time (PT) from baseline was reported for all treated participants. Baseline measurements were assessed up to 24 hours prior to Day 1 dosing.

Time frame:
From 24 hours pre-dose to 72 hours post-dose
Reported as:
Mean · maximum percent change from baseline
Mean Maximum Percent Change From Baseline Prothrombin Time (PT) Following a Single 5 mg Oral Dose of Apixaban
maximum percent change from baselineNormal Renal FunctionESRD Dose Before HemodialysisESRD Dose After Hemodialysis
Mean Maximum Percent Change From Baseline Prothrombin Time (PT) Following a Single 5 mg Oral Dose of Apixaban32.4 ± 58.3116.9 ± 10.9817.4 ± 7.28
SecondaryMean Maximum Percent Change From Baseline Activated Partial Thromboplastin Time (aPTT) Following a Single Oral Dose of 5 mg Apixaban

The mean maximum percent change in Activated Partial Thromboplastin Time (aPTT) from baseline was reported for all treated participants. Baseline measurements were assessed up to 24 hours prior to Day 1 dosing.

Time frame:
From 24 hours pre-dose to 72 hours post-dose
Reported as:
Mean · maximum percent change from baseline
Mean Maximum Percent Change From Baseline Activated Partial Thromboplastin Time (aPTT) Following a Single Oral Dose of 5 mg Apixaban
maximum percent change from baselineNormal Renal FunctionESRD Dose Before HemodialysisESRD Dose After Hemodialysis
Mean Maximum Percent Change From Baseline Activated Partial Thromboplastin Time (aPTT) Following a Single Oral Dose of 5 mg Apixaban19.9 ± 20.407.0 ± 9.6223.0 ± 14.81
SecondaryMean Peak Anti-FXa Activity Following a Single Oral Dose of 5 mg Apixaban

Anti-FXa activity was assessed from an activity-time profile for doses both before and after hemodialysis. Maximal means were reported in International Units per milliliter (IU/mL).

Time frame:
From 24 hours pre-dose to 72 hours post-dose
Reported as:
Mean · IU/mL
Mean Peak Anti-FXa Activity Following a Single Oral Dose of 5 mg Apixaban
IU/mLNormal Renal FunctionESRD Dose Before HemodialysisESRD Dose After Hemodialysis
Mean Peak Anti-FXa Activity Following a Single Oral Dose of 5 mg Apixaban1.47 ± 0.6591.03 ± 0.4911.29 ± 0.579
Other pre-specifiedNumber of Participants With Laboratory Marked Abnormalities

ULN=Upper Limit of Normal, LLN=Lower Limit of Normal, Pre-Rx= Baseline value. BUN=Blood Urea Nitrogen (mmol/L=millimoles per Liter): High if BUN \> 1.1\*ULN (if Pre-Rx\>ULN: \>1.25\*Pre-Rx). Platelet count (\*10\^9 cell/L): Low if Platelet Count \< 0.85\*LLN (if Pre-Rx\<LLN: \<0.85\*Pre-Rx). Creatine (umol/L=micromoles per Liter): High if Creatine \> 1.5\*ULN (if Pre-Rx\>ULN: \>1.33\*Pre-Rx). Calcium, Total (mmol/L): High if Calcium \> 1.5\*ULN (if Pre-Rx\>ULN: \>1.33\*Pre-Rx). Potassium, serum (mmol/L): High if Potassium \> 1.1\*ULN (if Pre-Rx\>ULN: \>1.1\*Pre-Rx; if Pre-Rx\<LLN: \>ULN). Phosphorus, Inorganic (mmol/L): Low if Phosphate \< 0.85\*LLN (if Pre-Rx\>ULN: \<LLN). Lactate dehydrogenase (U/L=Units per Liter): High if Lactate Dehydrogenase \> 1.25\*ULN (if Pre-Rx\>ULN: \>1.5\*Pre-Rx).

Time frame:
From 24 hours pre-dose to 72 hours post-dose
Reported as:
Number · participants
Number of Participants With Laboratory Marked Abnormalities
participantsNormal Renal FunctionESRD Maintained With Hemodialysis
BUN04
Platelet count01
Creatine01
Potassium01
Phosphorus01
Lactate dehydrogenase01
Other pre-specifiedNumber of Participants Who Died or Experienced Serious Adverse Events (SAEs) or Adverse Events Leading to Discontinuation

The number of participants who died or experienced SAEs or AEs leading to discontinuation was reported for each arm. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug. Grade (Gr) 1=Mild, Gr 2=Moderate, Gr 3=Severe, Gr 4= Potentially Life-threatening or disabling.

Time frame:
From Day 1 to 30 days post study discontinuation
Reported as:
Number · participants
Number of Participants Who Died or Experienced Serious Adverse Events (SAEs) or Adverse Events Leading to Discontinuation
participantsNormal Renal FunctionESRD Maintained With Hemodialysis
Deaths00
SAEs00
AEs leading to discontinuation00

Adverse events

Collected over From Day 1 until 30 days post discontinuation, up to September 2011 (approximately 3 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Normal Renal Function—0/8 (0%)0/8 (0%)
ESRD Dose Before Hemodialysis—0/8 (0%)2/8 (25%)
ESRD Dose After Hemodialysis—0/8 (0%)1/8 (12.5%)
Most frequent other events
Most frequent other events
EventNormal Renal FunctionESRD Dose Before HemodialysisESRD Dose After Hemodialysis
HeadacheNervous system disorders0/81/81/8
ConstipationGastrointestinal disorders0/81/80/8
Influenza like illnessGeneral disorders0/81/80/8
SomnolenceNervous system disorders0/81/80/8
Procedural hypotensionInjury, poisoning and procedural complications0/81/80/8

Baseline characteristics

All treated participants

Age, Continuous
Age, Continuous(years)Normal Renal FunctionESRD Maintained With HemodialysisTotal
Mean47.0 ± 7.746.9 ± 7.946.9 ± 7.5
Sex: Female, Male
Sex: Female, Male(Participants)Normal Renal FunctionESRD Maintained With HemodialysisTotal
Female224
Male6612
08

Study locations

1 site
  • Orlando, Florida, United States
09

References and documents

Publications

  • Wang X, Tirucherai G, Marbury TC, Wang J, Chang M, Zhang D, Song Y, Pursley J, Boyd RA, Frost C. Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis. J Clin Pharmacol. 2016 May;56(5):628-36. doi: 10.1002/jcph.628. Epub 2015 Dec 22. PubMed 26331581 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2011, a primary completion of Sep 2011 and a completion of Sep 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2016, 5 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2011
First posted
Apr 22, 2011
Start
Jun 2011
Primary completionActual
Sep 2011
CompletionActual
Sep 2011
Results first posted
Oct 11, 2016
Last update
Oct 11, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 11, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01340586
Responsible party
Sponsor
First posted
Apr 22, 2011
Start date
Jun 2011
Primary completion
Sep 2011
Completion
Sep 2011
Results posted
Oct 11, 2016
Last update
Oct 11, 2016

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apixaban

Start the discussion